TriKEs targeting the NKG2D receptor ligand ULBP2 (ULBP2/aCD19/aCD19 and ULBP2/aCD19/aCD33 TriKEs) have demonstrated a meaningful in vitro and in vivo anti-tumor activity against CLL (71). The gene discussed is ULBP2; the disease is B-cell chronic lymphocytic leukemia.